JPMorgan raised the firm’s price target on Ideaya Biosciences to $41 from $35 and keeps an Overweight rating on the shares. The analyst updated models in the SMid cap biotechnology group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences to hold a virtual meeting
- Ideaya Biosciences price target lowered to $44 from $48 at Guggenheim
- Ideaya Biosciences price target raised to $40 from $35 at Oppenheimer
- Ideaya Biosciences reports Q3 EPS (46c), consensus (49c)
- IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
